Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

About this update from Supernus Pharmaceuticals, Inc.

Engagement Includes CNS Portfolio and Digital Ecosystem CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- MERGE announces its selection as the Agency of Record (AOR) for Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a dynamic biopharmaceutical company dedicated to developing cutting-edge treatments for central nervous system (CNS) diseases. With AI rapidly reshaping the medical marketing landscape, Supernus is moving to embrace a future where human creativity meets the science of data and technology. This expanded partnership, which unifies Supernus’ digital marketing and technology platforms, is designed to leverage MERGE's core philosophy—building a blueprint for human-AI collaboration—to redefine healthcare communication experiences. “MERGE has been a trusted partner, consistently delivering innovative strategies and high-quality execution,” said Rebecca Lannan, Vice President of Marketing at Supernus. “MERGE’s history with us demonstrates their ability to consistently deliver fundamentally sound tactics that have contributed to our success. This expanded role reflects that MERGE is not only our digital AOR but also a comprehensive partner whose support spans all our personal promotion efforts, and supports two sales forces with the necessary resources for execution. MERGE’s expertise and deep understanding of our mission make them the ideal choice to partner with us on this journey.” In this expanded agreement, MERGE will lead omnichannel marketing strategy and expand the existing Supernus partnership beyond the Parkinson’s portfolio by securing the AOR assignment for QELBREE® (viloxazine extended-release capsules), a non-stimulant for the treatment of ADHD. As part of this expanded engagement, MERGE also assumes leadership of Supernus' full digital ecosystem, including website development and CRM operations. MERGE will continue to drive success for Supernus’ Parkinson’s disease brands: APOKYN® (apomorphine hydrochloride), GOCOVRI® (amantadine extended-release capsules), and ONAPGO™ (apomorphine hydrochloride). Using Contextual Spectrum™, MERGE will help Supernus deliver the right brand information and personalized experiences through compliant and tailored digital interactions with appropriate audiences. “This expanded agreement marks the evolution of a dynamic, seven-year relationship built on a foundation of trust and a unified vision for transfo...

View stock analysis, news, and events for Supernus Pharmaceuticals, Inc.